Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Eli Lilly and (NASDAQ:LLY ) Share Price
Media coverage about Eli Lilly and (NASDAQ:LLY
) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4641172686621 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Eli Lilly and (NASDAQ:LLY
) opened at 82.05 on Friday. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $86.72. The stock has a market cap of $86.56 billion and a P/E ratio of 35.50. The company has a 50-day moving average price of $83.00 and a 200 day moving average price of $81.69.
ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/11/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-eli-lilly-and-nasdaqlly-share-price.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.